{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:16:20Z","timestamp":1790644580918,"version":"4.1.0"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Endocr Metab"],"published-print":{"date-parts":[[2013]]},"DOI":"10.4103\/2230-8210.113725","type":"journal-article","created":{"date-parts":[[2013,6,20]],"date-time":"2013-06-20T06:03:53Z","timestamp":1371708233000},"page":"588","source":"Crossref","is-referenced-by-count":32,"title":["Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition"],"prefix":"10.4103","volume":"17","author":[{"given":"ReshamRaj","family":"Poudel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/2230-8210.113725-1","first-page":"667","volume-title":"Lilly lecture 1987.The triumvirate: Beta-cell, muscle, liver: A collusion responsible for NIDDM","author":"DeFronzo","year":"1988","journal-title":"Diabetes"},{"key":"key-10.4103\/2230-8210.113725-2","first-page":"773","volume-title":"Banting lecture.From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus","author":"Defronzo","year":"2009","journal-title":"Diabetes"},{"key":"key-10.4103\/2230-8210.113725-3","first-page":"650","volume-title":"Sodium-glucose co-transport inhibition with dapagliflozin in type 2 diabetes mellitus","author":"List","year":"2009","journal-title":"Diabetes Care"},{"key":"key-10.4103\/2230-8210.113725-4","first-page":"510","volume-title":"The sodium\/glucose cotransport family SLC5","author":"Wright","year":"2004","journal-title":"Pflugers Arch"},{"key":"key-10.4103\/2230-8210.113725-5","doi-asserted-by":"crossref","unstructured":"Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med 2007;261:32-43","DOI":"10.1111\/j.1365-2796.2006.01746.x"},{"key":"key-10.4103\/2230-8210.113725-6","unstructured":"Ganong WF. Renal function and micturition. In: Ganong WF, editor. Review of medical physiology. 21 st ed. New York: McGraw-Hill Companies; 2003. p. 702-30."},{"key":"key-10.4103\/2230-8210.113725-7","first-page":"782","volume-title":"Inhibition of renal glucose absorption: A novel strategy for achieving glucose control in type 2 diabetes mellitus","author":"Abdul-Ghani","year":"2008","journal-title":"Endocr Pract"},{"key":"key-10.4103\/2230-8210.113725-8","first-page":"5","volume-title":"The role of the kidneys in glucose homeostasis: A new path towards normalizingglycaemia","author":"DeFronzo","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/2230-8210.113725-9","first-page":"993","volume-title":"Molecular physiology of sodium-glucose cotransporters","author":"Hediger","year":"1994","journal-title":"Physiol Rev"},{"key":"key-10.4103\/2230-8210.113725-10","first-page":"551","volume-title":"SGLT2 inhibition: A novel strategy for diabetes treatment","author":"Chao","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"key-10.4103\/2230-8210.113725-11","first-page":"2873","volume-title":"Molecular analysis of the SGLT2 gene in patients with renal glucosuria","author":"Santer","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"key-10.4103\/2230-8210.113725-12","first-page":"125","volume-title":"Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose","author":"Farber","year":"1951","journal-title":"J Clin Invest"},{"key":"key-10.4103\/2230-8210.113725-13","first-page":"101","volume-title":"Maximum tubular reabsorption capacity for glucose and renal hemodynamics during rapid hypertonic glucose infusion in normal and diabetic subjects","author":"Mogensen","year":"1971","journal-title":"Scand J Clin Lab Invest"},{"key":"key-10.4103\/2230-8210.113725-14","first-page":"3427","volume-title":"Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes","author":"Rahmoune","year":"2005","journal-title":"Diabetes"},{"key":"key-10.4103\/2230-8210.113725-15","first-page":"125","volume-title":"Recent andemerging anti-diabetes targets","author":"Mohler","year":"2009","journal-title":"Med Res Rev"},{"key":"key-10.4103\/2230-8210.113725-16","first-page":"1565","volume-title":"10-Year follow-up of intensive glucose control in type 2 diabetes.UKPDS 80","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2230-8210.113725-17","first-page":"2545","volume-title":"Action to control cardiovascular risk in diabetes study group.Effects of intensive glucose lowering in type 2 diabetes","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2230-8210.113725-18","first-page":"2560","volume-title":"ADVANCE Collaborative Group.Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","author":"Patel","year":"2008","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2230-8210.113725-19","first-page":"129","volume-title":"VADT Investigators.Glucose control and vascular complications in veterans with type 2 diabetes","author":"Duckworth","year":"2009","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2230-8210.113725-20","first-page":"1219","volume-title":"Megatrials in type 2 diabetes.From excitement to frustration?","author":"Del","year":"2009","journal-title":"Diabetologia"},{"key":"key-10.4103\/2230-8210.113725-21","first-page":"98","volume-title":"Long-term treatment with sergliflozinetabonate improves disturbed glucose metabolism in KK-A (y) mice","author":"Katsuno","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"key-10.4103\/2230-8210.113725-22","first-page":"2041","volume-title":"Sodium-glucosetransporter-2 inhibition as an antidiabetic therapy","author":"Ferrannini","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"key-10.4103\/2230-8210.113725-23","first-page":"610","volume-title":"Glucose toxicity","author":"Rossetti","year":"1990","journal-title":"Diabetes Care"},{"key":"key-10.4103\/2230-8210.113725-24","first-page":"2197","volume-title":"Decreased in vivo glucose uptake but normal expression of GLUT1 and GLUT4 in skeletal muscle of diabetic rats","author":"Kahn","year":"1991","journal-title":"J Clin Invest"},{"key":"key-10.4103\/2230-8210.113725-25","first-page":"744","volume-title":"Regulation of endogenous glucose production by glucose per se is impaired in type 2 diabetes mellitus","author":"Mevorach","year":"1998","journal-title":"J Clin Invest"},{"key":"key-10.4103\/2230-8210.113725-26","first-page":"1794","volume-title":"T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes","author":"Oku","year":"1999","journal-title":"Diabetes"},{"key":"key-10.4103\/2230-8210.113725-27","first-page":"23","volume-title":"Increase in insulin response after treatment of overt maturity-onset diabetes is independent of the mode of treatment","author":"Kosaka","year":"1980","journal-title":"Diabetologia"},{"key":"key-10.4103\/2230-8210.113725-28","first-page":"578","volume-title":"Improved diabetic syndrome in C57BL\/KsJ-db\/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095","author":"Arakawa","year":"2001","journal-title":"Br J Pharmacol"},{"key":"key-10.4103\/2230-8210.113725-29","first-page":"510","volume-title":"Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: Effects on glycaemic control and body weight","author":"Zhang","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/2230-8210.113725-30","first-page":"1723","volume-title":"Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats","author":"Han","year":"2008","journal-title":"Diabetes"},{"key":"key-10.4103\/2230-8210.113725-31","unstructured":"Nauck M, Del Prato S, Rohwedder K, Elze M, Parikh S. Dapagliflozin vs glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin: 52-week results of a double-blind, randomised, controlled trial. Diabetologia 2010;53:S1-556."},{"key":"key-10.4103\/2230-8210.113725-32","first-page":"1656","volume-title":"A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: Applicability of a novel insulin-independent treatment","author":"Wilding","year":"2009","journal-title":"Diabetes Care"},{"key":"key-10.4103\/2230-8210.113725-33","first-page":"1510","volume-title":"Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats","author":"Rossetti","year":"1987","journal-title":"J Clin Invest"},{"key":"key-10.4103\/2230-8210.113725-34","doi-asserted-by":"crossref","unstructured":"Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: A review. Diabetes Metab Res Rev 2005;21:31-8.","DOI":"10.1002\/dmrr.532"},{"key":"key-10.4103\/2230-8210.113725-35","first-page":"590","volume-title":"Dapagliflozin for the treatment of type 2 diabetes","author":"Anderson","year":"2012","journal-title":"Ann Pharmacother"},{"key":"key-10.4103\/2230-8210.113725-36","first-page":"1020","volume-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","author":"Bolinder","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.113725-37","doi-asserted-by":"crossref","unstructured":"Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, et al.; Dapagliflozin 006 Study Group. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: A randomized trial. Ann Intern Med 2012;156:405-15.","DOI":"10.7326\/0003-4819-156-6-201203200-00003"},{"key":"key-10.4103\/2230-8210.113725-38","first-page":"890","volume-title":"SGLT2 deletion improves glucose homeostasis andpreserves pancreatic beta-cell function","author":"Jurczak","year":"2011","journal-title":"Diabetes"},{"key":"key-10.4103\/2230-8210.113725-39","first-page":"255","volume-title":"A paradigm shift in diabetes therapy: Dapagliflozin and other SGLT2 inhibitors","author":"Chao","year":"2011","journal-title":"Discov Med"},{"key":"key-10.4103\/2230-8210.113725-40","first-page":"507","volume-title":"FDA rejects novel diabetes drug over safety fears","author":"Burki","year":"2012","journal-title":"Lancet"},{"key":"key-10.4103\/2230-8210.113725-41","unstructured":"Liscinsky M. FDA approves Invokana to treat type 2 diabetes: First in a new class of diabetes drugs. Fda.gov [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; c2010 [updated 2013 Mar 29; cited 2013 Apr 2]. Available from: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm345848.htm."},{"key":"key-10.4103\/2230-8210.113725-42","first-page":"372","volume-title":"Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise","author":"Stenl\u00f6f","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"key-10.4103\/2230-8210.113725-43","doi-asserted-by":"crossref","unstructured":"Polidori D, Sha S, Mudaliar S, Ciaraldi TP, Ghosh A, Vaccaro N, et al. Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion: Results of a randomized, placebo-controlled study. Diabetes Care 2013 Feb 14. [In Press]","DOI":"10.2337\/dc12-2391"},{"key":"key-10.4103\/2230-8210.113725-44","first-page":"463","volume-title":"Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease","author":"Yale","year":"2013","journal-title":"Diabetes Obes Metab"}],"container-title":["Indian Journal of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:26:47Z","timestamp":1786649207000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/2230-8210.113725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013]]}},"alternative-id":["113725"],"URL":"https:\/\/doi.org\/10.4103\/2230-8210.113725","relation":{},"ISSN":["2230-8210"],"issn-type":[{"value":"2230-8210","type":"print"}],"subject":[],"published":{"date-parts":[[2013]]}}}